RESPIRATORY DISEASE PSI is a leading, full-service CRO specializing in on-time delivery of clinical studies. PSIs expertise in respiratory indications has been cultivated since our inception in 1995. With a turnover rate of <5% you can be assured that the knowledge of the nuances and complexities associated with conducting respiratory studies remains at PSI.
PSI has extensive Phase I-IV experience in diseases affecting the Respiratory Tract: Allergic Rhinitis †
Cystic Fibrosis †
Asthma †
Hospital Acquired Pneumonia
Chronic Bronchitis
Lung Cancer
Community Acquired Pneumonia
Respiratory Syncytial Virus †
Chronic Obstructive Pulmonary Disease
Ventilator Acquired Pneumonia
†
includes Pediatric subjects
PSIs dedicated Feasibility Department, comprised of medical specialists, laboratory experts, imaging specialists, logisticians and regulatory experts, have conducted feasibility across a wide range of respiratory indication, beginning at the RFP stage. When we apply this process to your trial, we are able to provide recommendations for the best choice of sites, geography and realistic timelines for your study.
I have found that PSI is the perfect choice for us a collaborating partner. Director of Clinical Research, Sweden
For more information about PSI, please visit our website WWW.PSI-CRO.COM or reach us at CONTACT@PSI-CRO.COM
PSI CRO AG Corporate Headquarters Baarerstrasse 113a 6300 Zug, Switzerland Tel: +41 41 228 10 00
Global Office Locations North America Ft. Washington, PA Burlingame, CA San Francisco, CA
Latin America Buenos Aires, Argentina
Europe Oxford, UK Munich, Germany Neusiedl am See, Austria Minsk, Belarus Sofia, Bulgaria Prague, Czech Republic Tallinn, Estonia Budapest, Hungary Milan, Italy Warsaw, Poland Bucharest, Romania Belgrade, Serbia Kiev, Ukraine Russian Federation: St. Petersburg, Moscow, Novosibirsk
Operational Presence by Region North America / Europe / Latin America Asia-Pacific / South Africa
WWW.PSI-CRO.COM